Difference between revisions of "Borjesson PK, et al. Clin. Cancer Res. (2003) cited as Ref 552 in DOI: 10.1038/s41392-020-0110-5 (Q9815)"
Jump to navigation
Jump to search
(Created claim: title (P93): Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma, #quickstatements; #temporary_batch_1590010982689) |
(Created claim: Page(s) (P105): 3961s-3972s, #quickstatements; #temporary_batch_1590074839150) |
||
| Property / Page(s) | |||
| + | 3961s-3972s | ||
| Property / Page(s): 3961s-3972s / rank | |||
| + | Normal rank | ||
Latest revision as of 15:45, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Borjesson PK, et al. Clin. Cancer Res. (2003) cited as Ref 552 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Borjesson PK
0 references
2003
0 references
Clin. Cancer Res.
0 references
9
0 references
Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma (English)
0 references
3961s-3972s
0 references
